Sritara, Piyamitr
4 papers on CoChatORCID 0000-0003-0509-8943
Most cited papers
- Verified
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., et al. (2014) · European Heart Journal
Peripheral Artery Disease ManagementLipoproteins and Cardiovascular Health
Cited by 318
- Verified
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 315
- Verified
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology
Peroxisome Proliferator-Activated ReceptorsLipoproteins and Cardiovascular Health
Cited by 140
- Verified
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis
Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine
Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension
Cited by 109
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free